Ocugen (OCGN) Capital Leases (2018 - 2019)
Ocugen (OCGN) reported Capital Leases of $17339.0 for Q3 2019, down 48.58% quarter-over-quarter from $33720.0 in Q4 2018.
Ocugen (OCGN) Capital Leases (2018 - 2019) Analysis & Trends
Ocugen has reported Capital Leases for 2 years, with the latest figure at $17339.0 in Q3 2019.
- For the quarter ending Q3 2019, Capital Leases changed N/A year-over-year to $17339.0; the trailing twelve-month figure through Sep 2019 stood at $17339.0 (changed N/A YoY), and the FY2018 full-year result was $33720.0, changed N/A from the prior year.
- Capital Leases for Q3 2019 stood at $17339.0, down from $33720.0 in the prior quarter.
- The five-year high for Capital Leases was $33720.0 in Q4 2018, with the low at $17339.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 17,339.00 |
| Dec 31, 2018 | 33,720.00 |